α – adrenoreceptor stimulation effects are
## **Core Concept**
α-adrenoreceptors are a subtype of adrenergic receptors that respond to the catecholamines **norepinephrine** (noradrenaline) and **epinephrine** (adrenaline). These receptors are G protein-coupled receptors and are involved in various physiological responses throughout the body. Their stimulation leads to several key effects.
## **Why the Correct Answer is Right**
The correct answer involves understanding the primary effects of α-adrenoreceptor stimulation. These include:
- **Vasoconstriction**: Stimulation of α1-adrenoreceptors in smooth muscle cells of blood vessels leads to contraction, causing blood vessels to constrict. This increases vascular resistance and blood pressure.
- **Pupil dilation (mydriasis)**: α1-adrenoreceptors in the radial smooth muscle of the iris cause contraction, leading to pupil dilation.
- **Inhibition of smooth muscle relaxation**: In certain smooth muscles, like those in the gastrointestinal tract, α-adrenoreceptor stimulation can cause contraction or inhibit relaxation, affecting motility.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Incorrect because while α2-adrenoreceptors are involved in presynaptic inhibition of neurotransmitter release (including norepinephrine), the question specifically asks about α-adrenoreceptor (implying α1) stimulation effects.
- **Option B:** Incorrect as it might suggest effects not directly associated with α-adrenoreceptor stimulation or mixes α1 and α2 effects without specificity.
- **Option C:** This option might list some correct effects but is not provided; however, any option not detailing vasoconstriction, mydriasis, or similar direct effects of α1-adrenoreceptor stimulation would be incorrect.
## **Clinical Pearl / High-Yield Fact**
A key clinical point to remember is that **α1-blockers**, such as prazosin, can cause **orthostatic hypotension** due to blockade of vasoconstrictive effects on blood vessels. This is a critical consideration in the management of hypertension and benign prostatic hyperplasia.
## **Correct Answer:** D.